A Poetry Reading by Rigoberto González

Rigoberto Gonzalez / Photo by Marion Ettlinger

Rigoberto González is the author four books of poetry, most recently Unpeopled Eden, which won the Lambda Literary Award and the Lenore Marshall Prize from the Academy of American Poets. His ten books of prose include two bilingual children's books, the three young adult novels in the Mariposa Club series, the novel Crossing Vines, the story collection Men Without Bliss, and three books of nonfiction, including Butterfly Boy: Memories of a Chicano Mariposa, which received the American Book Award from the Before Columbus Foundation. He also edited Camino del Sol: Fifteen Years of Latina and Latino Writing and Alurista's new and selected volume Xicano Duende: A Select Anthology. The recipient of Guggenheim, NEA and USA Rolón fellowships, a NYFA grant in poetry, the Shelley Memorial Award from the Poetry Society of America, The Poetry Center Book Award, and the Barnes & Noble Writer for Writers Award, he is contributing editor for Poets & Writers Magazine and is professor of English at Rutgers-Newark, the State University of New Jersey. In 2015, he received The Bill Whitehead Award for Lifetime Achievement from the Publishing Triangle. As of 2016, he serves as critic-at-large with the Los Angeles Times and sits on the Board of Trustees of the Association of Writers and Writing Programs (AWP). He earned graduate degrees from the University of California, Davis, and Arizona State University in Tempe.

Doors open at 6:30 p.m. and the reading will begin at 7 p.m. A booksigning will follow.

Hosted by the ASU Department of English and its Creative Writing Program, along with the Humanities Division of the College of Liberal Arts and Sciences.

Download flyer: PDF icon gonzalezreading16.pdf

Note that González will also give a talk about his writing career on Tues., Nov. 8 at 1:30 p.m. in the Fulton Center room 2490.

Jennifer Irish
Monday, Nov. 7, 2016, 7 p.m.
Pima Auditorium, 230
Memorial Union (MU)
Tempe campus
Free of charge and open to the public.

COVID-19 information

Latest updates  |  Coronavirus FAQ page  |  Vaccine FAQ page